NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company has conducted preclinical testing that has shown dramatic results and has been awarded an important FDA designation. We believe the future looks incredibly bright and urge investors to investigate NRXBF.
